Thomas J. Schall, President and CEO at ChemoCentryx, Inc. (CCXI), sold 221,348 shares at $55.33 ($12.4M) on 2020-05-11, disclosed to the SEC on 2020-05-12.
Open-market sale of $12.4M CCXI by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.01 | 4,201 | $231K | 1.9% |
| 2 | $55.01 | 4,201 | $231K | 1.9% |
| 3 | $55.33 | 54,579 | $3.0M | 24.3% |
| 4 | $55.33 | 54,579 | $3.0M | 24.3% |
| 5 | $56.14 | 16,029 | $900K | 7.2% |
| 6 | $56.14 | 16,029 |
| $900K |
| 7.2% |
| 7 | $57.75 | 35,865 | $2.1M | 16.6% |
| 8 | $57.75 | 35,865 | $2.1M | 16.6% |
| Total | $56.22 avg | 221,348 | $12.4M | 100% |
| Filing → |
| IMRX | BUY | 2025-06-18 | $179K | — | Filing → |
| IMRX | BUY | 2024-03-25 | $7K | — | Filing → |
| CCXI | SELL | 2022-08-08 | $6.5M | — | Filing → |